The results of a phase 2 study looking at Padcev and Keytruda combination therapy for patients with metastatic urothelial cancer shows promise with a 73% response that did not differ for a patient’s PDL1 status.
Jonathan Rosenberg, M.D.
Advertisement
Articles by Jonathan Rosenberg, M.D.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Diagnosed at 25 With Hodgkin's Lymphoma, She Says This Saved Her Life
2
Minimally Invasive Options in Rectal Cancer: TAMIS and Robotic Surgery
3
RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough
4
Why I Don’t Want to Hear “You’ll Beat This” After a Metastatic Breast Cancer Diagnosis
5